Entera Bio (NASDAQ:ENTX) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a research report report published on Friday morning, Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Entera Bio Price Performance

Shares of Entera Bio stock opened at $2.01 on Friday. The business has a 50 day simple moving average of $1.76 and a two-hundred day simple moving average of $1.94. The stock has a market capitalization of $71.93 million, a P/E ratio of -7.18 and a beta of 1.57. Entera Bio has a 12 month low of $0.52 and a 12 month high of $3.35.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The company had revenue of $0.06 million during the quarter. As a group, research analysts anticipate that Entera Bio will post -0.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Entera Bio stock. Virtu Financial LLC acquired a new position in Entera Bio Ltd. (NASDAQ:ENTX) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 22,040 shares of the company’s stock, valued at approximately $37,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.